UY25876A1 - Derivados del ácido aril-carboxílico y del tetrazol - Google Patents

Derivados del ácido aril-carboxílico y del tetrazol

Info

Publication number
UY25876A1
UY25876A1 UY25876A UY25876A UY25876A1 UY 25876 A1 UY25876 A1 UY 25876A1 UY 25876 A UY25876 A UY 25876A UY 25876 A UY25876 A UY 25876A UY 25876 A1 UY25876 A1 UY 25876A1
Authority
UY
Uruguay
Prior art keywords
compounds
independently
incorrect
aryl
heterocyclyl
Prior art date
Application number
UY25876A
Other languages
English (en)
Inventor
Daniel Lee Severance
Counde O Yang
Francisco Javier Lopez-Tapia
Alexander Victor Muehldorf
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY25876A1 publication Critical patent/UY25876A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compuestos que son moduladores generales del receptor de IP, en particular agonistas del receptor de IP, y que están representados por la fórmula general (I) representada en la figura 1, e isómeros individuales, mezclas racémicas o no racémicas de isómeros, o sales farmacéuticamente aceptables o solvatos de los mismos, donde: R1 y R2 son cada uno independientemente en cada caso, alquilo, arilo, aralquilo, heteroarilo, cicloalquilo o heterociclilo; R3 y R4 son cada uno independientemente en cada caso, hidrógeno, alquilo, alcoxi, amino, halógeno, haloalquilo, hidroxialquilo, nitro, arilo, aralquilo o heterociclilo; A es independientemente en cada caso alquileno o alquenileno; B es independientemente en cada caso -O-(CH2)m- o -(CH2)n-. También se incluyen procesos para la fabricación de los compuestos de fórmula (I). Ejemplos de compuestos de fórmula general (I): Ácido [3-[difenilcarbamoiloximetil]-2-metilfenoxi}acético; Ácido cis-{3-[3-(benzilfenilcarbamoiloxipropenil)-fenoxi]acético; Ácido cis-{3-[3-(difenilcarbamoiloxipropenil)-fenil] propiónico; entre otros. Se incluyen composiciones farmacéuticas que contienen tales compuestos y a un excipiente adecuado, y a métodos para su uso como agentes terapéuticos en enfermedades asociadas por ejemplo: con la curación incorrecta de heridas, necrosis de tejido, contracción uterina prematura, ulceración gástrica, disfunción sexual, dolor menstrual grave, inmunoregulación incorrecta, agregación plaquetaria incorrecta o función de los neutrófilos incorrecta, entre otras posibilidades.
UY25876A 1998-12-23 1999-12-22 Derivados del ácido aril-carboxílico y del tetrazol UY25876A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11344698P 1998-12-23 1998-12-23
US15181499P 1999-08-30 1999-08-30

Publications (1)

Publication Number Publication Date
UY25876A1 true UY25876A1 (es) 2001-07-31

Family

ID=26811078

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25876A UY25876A1 (es) 1998-12-23 1999-12-22 Derivados del ácido aril-carboxílico y del tetrazol

Country Status (29)

Country Link
US (1) US6335459B1 (es)
EP (1) EP1013639B1 (es)
JP (1) JP3415085B2 (es)
KR (1) KR100378335B1 (es)
CN (1) CN1167670C (es)
AR (1) AR029320A1 (es)
AT (1) ATE251125T1 (es)
AU (1) AU735640B2 (es)
BR (1) BR9905974A (es)
CA (1) CA2292921C (es)
DE (1) DE69911726T2 (es)
DK (1) DK1013639T3 (es)
ES (1) ES2207108T3 (es)
HR (1) HRP990394A2 (es)
HU (1) HUP9904659A3 (es)
ID (1) ID25983A (es)
IL (1) IL133578A (es)
MA (1) MA26713A1 (es)
NO (1) NO316171B1 (es)
NZ (1) NZ501891A (es)
PE (1) PE20001368A1 (es)
PL (1) PL337419A1 (es)
PT (1) PT1013639E (es)
RU (1) RU2179969C2 (es)
SG (1) SG90086A1 (es)
TR (1) TR199903310A3 (es)
TW (1) TWI221834B (es)
UY (1) UY25876A1 (es)
YU (1) YU69699A (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
SE0100158D0 (sv) * 2001-01-19 2001-01-19 Synphora Ab Novel method and composition for local treatment of Meniere´s disease and tinnitus
MXPA03007864A (es) * 2001-03-02 2003-12-04 Hoffmann La Roche Derivados del acido alcoxicarbonilamino-heteroaril carboxilico como antagonistas ip.
ES2636943T3 (es) 2003-05-09 2017-10-10 Toray Industries, Inc. Beraprost y un inhibidor del sistema renina-angiotensina para usar en el tratamiento de enfermedades renales
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
US9669381B2 (en) 2007-06-27 2017-06-06 Hrd Corporation System and process for hydrocracking
KR20220031743A (ko) 2008-03-18 2022-03-11 아레나 파마슈티칼스, 인크. 프로스타시클린 （ｐｇｉ２） 수용체와 관련된 장애의 치료에 유용한 상기 수용체의 조절제
KR101587071B1 (ko) * 2008-07-23 2016-01-20 도레이 카부시키가이샤 만성 신부전 처치제
WO2011154827A2 (en) 2010-06-11 2011-12-15 Rhodes Technologies Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
CA2802294C (en) 2010-06-11 2016-05-10 Rhodes Technologies Process for n-dealkylation of tertiary amines
KR102432505B1 (ko) 2017-03-01 2022-08-12 아레나 파마슈티칼스, 인크. Pgi2-수용체 효능제를 포함하는 조성물 및 그의 제조 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1079414A (en) 1965-06-30 1967-08-16 Smith & Nephew Derivatives of acetic acid and a process for their preparation
GB1185539A (en) 1967-11-03 1970-03-25 Smith & Nephew Substituted Tetrazoles
DE2432560A1 (de) 1974-07-06 1976-01-22 Boehringer Mannheim Gmbh Neue phenoxyalkylcarbonsaeurederivate und verfahren zur herstellung derselben
JPS5832859A (ja) 1981-08-20 1983-02-25 Dainippon Pharmaceut Co Ltd Ｎ，ｎ−ジメチルカルバミン酸ベンジルエステル誘導体
JPH0725725B2 (ja) 1987-07-23 1995-03-22 保土谷化学工業株式会社 ベンズアミド誘導体
US5084466A (en) 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
CA2090283A1 (en) 1992-02-28 1993-08-29 Nobuyuki Hamanaka Phenoxyacetic acid derivatives
CA2183063A1 (en) 1994-02-10 1995-08-17 Atsushi Ichikawa Prostaglandin i2 receptor
WO1995024393A1 (en) 1994-03-10 1995-09-14 Fujisawa Pharmaceutical Co., Ltd. Naphthalene derivatives as prostaglandin i2 agonists
US5753700A (en) 1994-12-28 1998-05-19 Ono Pharmaceutical Co., Ltd. Naphthyloxyacetic acid derivatives
TW401408B (en) 1995-07-21 2000-08-11 Fujisawa Pharmaceutical Co Heterocyclic compounds having prostaglandin I2 agonism
JP3909864B2 (ja) 1995-07-26 2007-04-25 小野薬品工業株式会社 ナフチルオキシ酢酸誘導体およびそれらを有効成分として含有する薬剤
AUPP029197A0 (en) 1997-11-10 1997-12-04 Fujisawa Pharmaceutical Co., Ltd. Benzocycloheptene derivatives
AUPP109097A0 (en) 1997-12-22 1998-01-22 Fujisawa Pharmaceutical Co., Ltd. Napthalene derivatives

Also Published As

Publication number Publication date
BR9905974A (pt) 2000-09-12
ES2207108T3 (es) 2004-05-16
NO996366D0 (no) 1999-12-21
PT1013639E (pt) 2004-02-27
MA26713A1 (fr) 2004-12-20
CN1167670C (zh) 2004-09-22
NO316171B1 (no) 2003-12-22
IL133578A (en) 2004-07-25
TR199903310A2 (xx) 2000-10-23
ID25983A (id) 2000-11-16
TWI221834B (en) 2004-10-11
TR199903310A3 (tr) 2000-10-23
PL337419A1 (en) 2000-07-03
DK1013639T3 (da) 2004-02-09
AR029320A1 (es) 2003-06-25
AU735640B2 (en) 2001-07-12
HUP9904659A2 (hu) 2000-11-28
DE69911726T2 (de) 2004-07-29
US6335459B1 (en) 2002-01-01
AU6534099A (en) 2000-07-06
YU69699A (sh) 2001-12-26
HU9904659D0 (en) 2000-02-28
HUP9904659A3 (en) 2000-12-28
PE20001368A1 (es) 2000-12-14
EP1013639A1 (en) 2000-06-28
EP1013639B1 (en) 2003-10-01
CA2292921A1 (en) 2000-06-23
JP3415085B2 (ja) 2003-06-09
SG90086A1 (en) 2002-07-23
CA2292921C (en) 2004-08-17
KR20000048322A (ko) 2000-07-25
RU2179969C2 (ru) 2002-02-27
NO996366L (no) 2000-06-26
DE69911726D1 (de) 2003-11-06
CN1266054A (zh) 2000-09-13
KR100378335B1 (ko) 2003-03-29
IL133578A0 (en) 2001-04-30
JP2000191523A (ja) 2000-07-11
ATE251125T1 (de) 2003-10-15
HRP990394A2 (en) 2000-08-31
NZ501891A (en) 2001-10-26

Similar Documents

Publication Publication Date Title
ES2260703T3 (es) Alquilaminas carentes de mitades imidazol domo ligandos del receptor h3 de histamina y sus aplicaciones terapeuticas.
NO304072B1 (no) Dekahydroisoqinolin-forbindelser som er eksitatoriske aminosyre reseptorantagonister og farmasöytisk formulering derav
UY25876A1 (es) Derivados del ácido aril-carboxílico y del tetrazol
EA200000481A1 (ru) Производные гидроксамовой кислоты в качестве ингибиторов металлопротеаз матрикса (мпм)
ES2900815T3 (es) Compuestos y métodos para inducir la condrogénesis
UY24206A1 (es) Feniliminoimidazolinas agonistas de alfa 1l útiles en el tratamiento de la incontinencia urinaria.
DE3762618D1 (de) Amidderivate.
RU2004104625A (ru) Аналоги простагландинов в качестве агонистов рецептора ep4
AU2001264012A1 (en) Novel calcium receptor active molecules and method for preparing same
AR030959A1 (es) Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen
ES2031876T3 (es) Un procedimiento para la preparacion de 5,6-dihidro-2-(fenil sustituido)-1,2,4,-triazin-3,5(2h,4h)-dionas.
FI80877B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara spiro/4,(3+n)/-2-azaalkan-3-karboxylsyraderivat och vid framstaellning av dessa anvaendbara foerening.
ECSP034602A (es) Derivados sustituidos 2-fenilaminoimidazolina fenil cetona como antagonistas ip
ES496074A0 (es) Un procedimiento para la preparacion de derivados de morfo- lina
ES2141957T3 (es) Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales.
EA200000785A1 (ru) Новые сульфонамидные производные в качестве ингибиторов рассасывания костной ткани и ингибиторов адгезии клеток
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
PT100942A (pt) Agentes antifungicos de triazole, processo para a sua preparacao e composicoes farmaceuticas que os contem
UY23624A1 (es) Procedimiento para la preparacion de nuevos derivados de indol
JP2004524345A5 (es)
ES2051834T3 (es) El uso de tetrahidrobenzeno(c,d)indol-6 carboxamidas para la preparacion de un medicamento para el tratamiento de la ansiedad.
SE8503055D0 (sv) Piperonylcarboxamido derivatives
AR009374A1 (es) Compuestos novedosos antagonistas de nmda (n-metil-d-aspartato), composicion farmaceutica y usos para fabricar medicamentos.
WO1995031988A1 (en) COMPOSITION CONTAINING 5HTIA and 5HTID ANTAGONISTS
NO167286C (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzotiazepin-derivater.

Legal Events

Date Code Title Description
ABAN Application deemed to be withdrawn (no publication fee paid)

Effective date: 20090323